Maze Therapeutics (MAZE) Earnings Date & Reports

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

MAZE is expected to report earnings to fall 4.55% to -62 cents per share on April 06

Maze Therapeutics MAZE Stock Earnings Reports

Q4'25

Est.

$-0.63

Q3'25

Missed

by $0.04

Q2'25

Missed

by $0.15

The last earnings report on November 06 showed earnings per share of -66 cents, missing the estimate of -62 cents. With 299.53K shares outstanding, the current market capitalization sits at 1.99B.

View a ticker or compare two or three

Compare

MAZE

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. MAZE showed earnings on November 06, 2025. You can read more about the earnings report here.

View AI-Driven Trading for MAZE

A.I. Advisor

published General Information

General Information

Industry Biotechnology

Profile

Fundamentals

Details